Slide 1: Q3 2023 Financial Results
The Joint Corp. | NASDAQ: JYNT | thejoint.com Q3 2023 Financial Results As of September 30, 2023 | Reported on November 9, 2023
Slide 2: Safe Harbor Statements
Safe Harbor Statements Certain statements contained in this presentation are "forward-looking statements” about future events and expectations. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our
Slide 3: © 2023 The Joint Corp. All Rights Reserved.
© 2023 The Joint Corp. All Rights Reserved. 3
Slide 4: Building upon Foundation for Growth
Building upon Foundation for Growth Q3 2023 Q3 2022 Revenue $29.5M $26.5M 8% 0% (5)% Loss on disposition or impairment3 $905k $264k Increase in Increase in Decrease in system-wide sales1 system–wide comp sales2 system–wide comp sales2 Operating (Loss)/Inc. $(898)k $732k Q3 2023 over Q3 2022 for all
Slide 5: 26 New Clinics in Q3 2023
26 New Clinics in Q3 2023 Q3 Q3 2023 2022 914 TOTAL CLINICS OPEN1 838 Franchise 136 Licenses Sold 12 12 Franchise Company Owned/Managed 126 706 Total New 96 579 Franchised 24 33 513 64 Clinics Opened 442 60 399 370 48 Greenfield 778 Clinics Opened 2 5 312 61 47 712 246 47 610 4 515 453 394 Franchise
Slide 6: Pipeline for Growth
Pipeline for Growth Franchise Licenses Sold Annually Clinics in Active Development1 Gross Cumulative Franchise Licenses Sold1 283 1243 1193 156 253 1118 235 962 126 121 204 202 841 99 715 155 616 75 112 50 37 Dec. 31, Dec. 31, Dec. 31, Dec. 31, Dec. 31, Dec. 31, Sept. 30, Dec. 31, Dec. 31, Dec. 31,
Slide 7: Implementing New Marketing Programs
Implementing New Marketing Programs Leveraging Data Growing New Leads and Patients Increasing Lifetime Patient Value Growing Brand Equity © 2023 The Joint Corp. All Rights Reserved. 7
Slide 8: Q3 2023 Financial Results as of Sept. 30, 2023
Q3 2023 Financial Results as of Sept. 30, 2023 $ in M1 Q3 2023 Q3 2022 Differences Revenue $29.5 $26.5 $3.0 11% • Corporate clinics 17.9 15.8 2.0 13% • Franchise fees 11.6 10.6 1.0 9% Cost of revenue 2.6 2.3 0.3 11% Sales and marketing 4.1 3.3 0.9 27% Depreciation and amortization 2.3 1.8 0.6 32% G&
Slide 9: YTD 2023 Financial Results as of Sept. 30, 2023
YTD 2023 Financial Results as of Sept. 30, 2023 $ in M1 YTD 2023 YTD 2022 Differences Revenue $87.1 $73.6 $13.5 18% • Corporate clinics 52.8 42.9 9.9 23% • Franchise fees 34.3 30.6 3.6 12% Cost of revenue 7.7 6.7 1.0 14% Sales and marketing 13.2 10.7 2.5 23% Depreciation and amortization 6.9 4.6 2.3
Slide 10: Reiterating 2023 Financial Guidance
Reiterating 2023 Financial Guidance 2022 2023 Low 2023 High $ in M Actual Guidance Guidance Revenues $101.9 $115.0 $118.0 Adjusted EBITDA $11.5 $11.0 $12.5 New Franchised Clinic Openings 121 100 120 New Greenfield Clinic1 16 8 12 1 Historically, company-owned or managed clinic openings included a co
Slide 11: Leading Market Growth
Leading Market Growth The Joint Corp. 12-yr. CAGR 62%1 vs. Industry 5-yr. CAGR 5.1%2 System-wide Sales People will ($ in M) continue to seek $435.3 more noninvasive, $361.1 $354.8 holistic ways to 62% CAGR1 manage their pain. (2010 - 2022) $260.0 $220.3 We’ll be there to $165.1 treat them. $126.9 $9
Slide 12: Driving Long-term Shareholder Value
Driving Long-term Shareholder Value The most powerful brand-building tool is our storefronts. © 2023 The Joint Corp. All Rights Reserved. 12
Slide 13: Performance Metrics and Non-GAAP Measures
Performance Metrics and Non-GAAP Measures This presentation includes commonly discussed performance metrics. System-wide sales include sales at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the
Slide 14: Q3 2023 Segment Results as of Sept. 30, 2023
Q3 2023 Segment Results as of Sept. 30, 2023 $ in 000s 2023 Q3 © 2023 © 2022 The The Joint Joint Corp. Corp. All All Rights Rights Reserved. Reserved. 14
Slide 15: YTD Segment Results through Sept. 30, 2023
YTD Segment Results through Sept. 30, 2023 $ in 000s 2023 YTD Q3 © 2023 © 2022 The The Joint Joint Corp. Corp. All All Rights Rights Reserved. Reserved. 15
Slide 16: GAAP – Non-GAAP Reconciliation
GAAP – Non-GAAP Reconciliation $ in 000s © 2023 The Joint Corp. All Rights Reserved. 16
Slide 17: Contact Information
Contact Information Peter D. Holt, President & CEO peter.holt@thejoint.com The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960 https://www.facebook.com/thejointchiro @thejointchiro Jake Singleton, CFO jake.singleton@thejoint.com https://twitter.com/thejointchir